AZD 1222
PreclinicalSmall molecule
AZD 1222 is one of 19 small molecule programs targeting COVID-19. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Nexavar
BayerPreclinical
Singulair
AstraZenecaPreclinical
Proventil
Mylan Pharmaceuticals IncPreclinical
Nitrostat
VViatris Specialty LLC
Preclinical
Rayaldee
OOrganon and Co
Preclinical
SARS-COV-2 VACCINE
ModernaPreclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Statins
SanofiPreclinical
Antihypertensive Agents
NNational Heart, Lung, and Blood Institute (NHLBI)
Preclinical
Conventional
PPopulation Health Research Institute
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AZD 1222. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity Medicine Greifswald